(North America, South America, and the Caribbean)
(Including Hong Kong SAR, Macau SAR, and Taiwan)
Novogene has genomic sequencing labs in the US at University of California Davis, UK, Germany, Singapore, China and Japan with a total area of nearly 40,000 m2 , including a 2,000 m2 GMP facility and a 2,000 m2 clinical laboratory. As of 2024, Novogene has established 10 lab facilities globally and collaborates with more than 7,300 global experts, sequencing over 3 million samples annually in our labs worldwide.
The Novogene Americas Sequencing Center at UC Davis was established in 2016. It is currently equipped with NovaSeq 6000 and NovaSeq X Plus sequencing platforms, providing NGS services and analysis for research customers in North and South America.
Novogene’s Cambridge Sequencing Center was established in May 2018 and moved to Cambridge Science Park in August 2019. The center is now equipped with automated workstations, multiple NovaSeq 6000s and high-performance computing clusters, and has passed GCLP certification. The NovaSeq X Plus system was added in March 2023.
In partnership with AITbiotech and the Genome institute of Singapore (GIS), NovogeneAIT Genomics has established one of the largest NGS laboratories in the Asia Pacific region. Since 2017, our state-of-the-art laboratory, located in Biopolis, Singapore, is equipped with 6 units of illumina NovaSeq 6000, 1 unit of the PacBio Sequel IIe, 10x Genomics Chromium Controller, and the Olink next-generation proteomics platform. These resources allow us to provide trusted, reliable, and cost-effective services to customers in the Asia Pacific, Middle East and Africa (AMEA) region.
In China, we use the most efficient technologies from the world’s leading suppliers, including the Illumina NovaSeq 6000 and NovaSeqX Plus, Oxford Nanopore, and the PacBio Revio and Sequel IIe systems. Currently, Tianjin Medical Laboratory has obtained CAP certification, and this world-class facility enables us to provide high-quality clinical sequencing services globally.
Our supercomputing capability allows us to analyze hundreds of thousands of whole human genomes per month. This capability aligns with our unsurpassed NGS capacity, enabling us to run many projects of different sizes and still deliver the data to our customers in a timely fashion. Our state-of-the-art platform is comprised of DELL computing nodes with total memory of 106 TB, computing power of up to 2,480T flops, and Isilon storage capacity of 25 PB. Our storage capacity can expand as our needs grow, ensuring our customers’ data is backed up and available as needed.
The field is required.
I agree that Novogene Corporation may use this information to contact me to assist with my request. I understand that all personal information I have submitted will be kept confidential in accordance with Novogene's privacy policy.